Congress

← vista completa

Published on May 1, 2007 | http://doi.org/10.5867/medwave.2007.04.883

Orlistat reduces blood pressure in obese patients independently of clinical context, especially in patients with baseline hypertension

Orlistat reduce la presión arterial en pacientes obesos en forma independiente del contexto clínico, especialmente en pacientes con hipertensión basal

Ian Caterson, Gory Wittert

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Ian Caterson

Human Nutrition Unit, University of Sydney, Sydney, Australia

Gory Wittert

Department of Medicine, University of Adelaide, Australia

Figures

Article has no figures.

Forum

No messages

History

Citation Caterson I, Wittert G. Orlistat reduces blood pressure in obese patients independently of clinical context, especially in patients with baseline hypertension. Medwave 2007;7(04):e883 doi: 10.5867/medwave.2007.04.883

Publication date 01/05/2007

Index

Article metrics

Article has no metrics.

Notes

References

  1. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss: an update of the l997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity and Metabolism. Circulation. 2006 Feb 14;113(6):898-918. Epub 2005 Dec 27. | CrossRef | PubMed
  2. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, et al. American Heart Association Council on Nutrition, Physical Activity and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004 Nov 2;110(18):2952-67. Epub 2004 Oct 27. | CrossRef | PubMed
  3. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Ortistat Improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov;20(11):2257-67. | CrossRef | PubMed
  4. Broom I, Wilding J, Stott P, Myers N; UK Multimorbidity Study Group. Randomized trial of the effect of orlistat on body weigth and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract. 2002 Sep;56(7):494-9. | PubMed
  5. Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA, et al. The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin. 2004 Sep;20(9):1393-401. | CrossRef | PubMed
  6. Guy-Grand B, Drouin P, Eschwège E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases - a six month randomized trial. Diabetes Obes Metab. 2004 Sep;6(5):375-83. | CrossRef | PubMed
  7. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61. | CrossRef | PubMed
  8. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005 Nov;7(6):699-708. | CrossRef | PubMed
  9. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL-Primary Health Care Trial. Diabetes Obes Metab. 2005 Jan;7(1):21-7. | CrossRef | PubMed